Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Operations: 2010-2025

Historic Cash from Operations for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $44.1 million.

  • Ani Pharmaceuticals' Cash from Operations rose 253.17% to $44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.7 million, marking a year-over-year increase of 83.77%. This contributed to the annual value of $64.0 million for FY2024, which is 46.19% down from last year.
  • Ani Pharmaceuticals' Cash from Operations amounted to $44.1 million in Q3 2025, which was down 41.89% from $75.8 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Cash from Operations' 5-year high stood at $75.8 million during Q2 2025, with a 5-year trough of -$18.9 million in Q1 2022.
  • Moreover, its 3-year median value for Cash from Operations was $21.4 million (2023), whereas its average is $30.7 million.
  • In the last 5 years, Ani Pharmaceuticals' Cash from Operations slumped by 4,865.15% in 2022 and then soared by 1,116.82% in 2023.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Cash from Operations stood at -$12.2 million in 2021, then surged by 63.89% to -$4.4 million in 2022, then soared by 1,116.82% to $44.7 million in 2023, then tumbled by 64.55% to $15.9 million in 2024, then skyrocketed by 253.17% to $44.1 million in 2025.
  • Its last three reported values are $44.1 million in Q3 2025, $75.8 million for Q2 2025, and $35.0 million during Q1 2025.